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Interventional studies are designed specifically to test 
the impact of a treatment or management strategy on an 
outcome of interest. These are frequently prospective 
studies that compare a treated cohort with control patients, 
and can take the form of randomized controlled trials, 
pre- and post-implementation comparisons, or non-
randomized trials (1). These study designs are better 
suited than retrospective observational studies to assess the 
causative effect of an intervention, but still have limitations 
and can be susceptible to different types of bias. Often, 
considerable effort and resources are required to plan and 
conduct an interventional study, and many factors can affect 
the eventual impact of the results.
In this article, we will highlight two viewpoints 
regarding the role of small or single-institution prospective 
interventional studies within the field of thoracic surgery: first, 
that these studies are beneficial and can positively impact the 
field, and second, that these studies can have such significant 
limitations that they may have no meaningful impact. A 
summary of these viewpoints is included in Table 1. We will 
also review elements that can make for successful design and 
execution of small prospective interventional studies.
Pro: these studies are beneficial and can 
positively impact the field
Small or single-institutional prospective studies can be 
employed for a variety of goals. These studies can be useful 
for analyzing elements of daily clinical care, adding data to 
dogmatic practice. They can also assess preliminary safety 
and efficacy of new or innovative clinical practices, establish 
feasibility of an intervention, or demonstrate proof of concept 
that provides the basis for a larger study. They may also be 
the ideal medium for collecting detailed subject patient data 
or communicating relevant clinical experiential data to the 
field. Several examples of such studies exist within thoracic 
surgery, and demonstrate the utility of this type of research.
Thoracic surgeons regularly use historical dogma to 
make daily clinical decisions, such as in the post-operative 
management of chest tubes, but there is often a lack of data 
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that support these decisions. Prospective studies can help fill 
the gap. Cerfolio and Bryant (2) produced a single-surgeon, 
prospective study to challenge the often-cited “rule” that 
it is unsafe to discontinue a chest tube with an output of 
250 mL/day or more. By applying a prospective algorithm 
of removing all chest tubes with less than 450 mL/day, 
without an air leak and without chylothorax, they found that 
over a 10-year period of over 8,600 pulmonary resections, 
only 0.55% of patients were readmitted for symptomatic 
pleural effusion. When compared to the overall group, the 
cohort of patients that had chest tubes discontinued with 
250–450 mL/day output had no significant difference 
in readmission rate. Additionally, patients that were 
discharged early on postoperative day 2 or 3 carried the 
same readmission rate as the rest of the population. The 
significance of small, perspective studies in the management 
of chest tubes is not confined to this study. Cerfolio et al. (3) 
also utilized a prospective randomized trial to shed light on 
whether water seal or suction is superior for resolving air 
leaks after elective pulmonary resection. After developing 
a system to quantify severity of air leaks, they followed 
postoperative leaks over time in preoperatively-randomized 
water seal and suction groups matched to control for risk 
factors of leak. The randomization aspect of the trial was 
halted after 67% of air leaks under water seal had resolved 
by postoperative day 3 and only 7% of leaks under suction 
had resolved by this time (P=0.001). They concluded 
that water seal is superior to suction for resolving mild to 
moderate air leaks according to their described severity 
ranking, however, patients with large air leaks are at risk for 
pneumothorax on water seal and should be placed to suction 
to avoid this complication. These types of findings would be 
difficult or impractical to study in a large randomized trial 
and allow surgeons to utilize data-driven evidence when 
making clinical patient care decisions. While the decision 
of when to transition to water seal and when to pull a chest 
tube may seem mundane, these types of daily considerations 
have real implications on length of stay, treatment costs, 
and the patient’s experience. Therefore, it is imperative that 
these decisions are evidence-based. Small, single-institution 
prospective studies can serve as a relatively quick, affordable, 
and generalizable source of evidence to better inform 
surgeons on daily clinical decisions that are often dictated by 
dogma and anecdotal evidence.
Small-scale prospective studies also have the potential to 
provide a relatively simple and timely means to evaluate the 
safety and efficacy of new interventions that are either not 
developed enough or not appropriate for more rigorous, 
large-scale, randomized studies. One example is the use 
of office spirometry for preoperative risk stratification 
before lung resection instead of the traditionally used 
formal laboratory-based spirometry. In a small-scale, 
prospective, single-institution clinical trial, Hudson et al. (4) 
created 52 clinical propensity matches between patients 
assessed with office spirometry or laboratory spirometry. 
Outcome analysis showed no statistical difference 
between the matched office spirometry and laboratory 
spirometry patients in terms of discharge from the hospital, 
30-day mortality, postoperative respiratory failure, major 
morbidity rate, and length of stay. The study also estimated 
that appropriately using office spirometry rather than 
laboratory spirometry would result in approximately 
$38,000 in annual institutional cost savings. In summary, 
Table 1 A summary of highlighted benefits and limitations of small 
prospective studies
Benefits
Can study individual elements of patient care
Can be quick and relatively inexpensive to conduct
Can assess preliminary safety of a new treatment
Can provide an estimate of efficacy of an intervention
Can establish proof of concept
Can establish feasibility of an intervention
Can collect detailed patient data beyond standard of care 
more easily from a smaller cohort
Can be useful to communicate experiential knowledge to the 
field
Can result in stepwise improvements to clinical care
Limitations
Can be subject to inadequate study design
Can be underpowered and subject to type II error
Can have false positive results, type I error, if rare events occur 
in a small population
Can be affected by confounding, may not be able to 
sufficiently adjust results due to sample size
Can have results that are not generalizable to other practice 
settings
Can have excessively strict enrollment criteria and lead to a 
test of efficacy rather than effectiveness
Can be susceptible to significant publication bias
Can be insufficient to change practice
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by appropriately implementing a single-institution, small-
scale, prospective clinical trial, Hudson et al. were able to 
effectively demonstrate the sufficiency, safety, and potential 
cost savings of using only office spirometry for preoperative 
pulmonary function screening before lung resection in 
low-risk patients. Findings like this can have practice-
changing implications in the field of thoracic surgery. At 
a minimum, prospective trials can serve as the first form 
of safety validation for newer diagnostic and treatment 
patterns that are not yet widely accepted or are still being 
scaled. The prospective study design is often able to show 
the potential efficacy, safety, and cost-savings for new 
clinical interventions by taking full advantage of single-
institution data that may otherwise be underutilized.
A limiting factor in executing large-multicenter 
trials is often cost. When a novel idea or intervention is 
presented in the surgical arena, demonstrating proof of 
concept can be valuable prior to organizing expensive 
multicenter trials. Smaller-scale studies can provide 
this preliminary assurance. Postoperative pneumonia 
after elective pulmonary resection is a common and 
life-threatening complication. In addition to affecting 
morbidity and mortality, postoperative pneumonia can 
greatly affect cost and length of stay. After recognizing 
that oral hygiene regimens lower ventilator-associated 
pneumonias, Washington University in St. Louis (5) 
designed a single-arm interventional study to assess 
the effect and feasibility of oral hygiene on pneumonia 
rates after pulmonary resection. This study enrolled 
62 patients into a pre- and postoperative chlorhexidine 
toothbrushing intervention cohort and compared their 
postoperative pneumonia rate (1.6%) to that of a time-
matched contemporaneous cohort (4.9%). While not 
statistically significant (P=0.35), this small-scale study 
showed an encouraging trend towards lower rates of 
pneumonia that supports further larger-scale studies, and 
provides a point estimate for appropriate statistical power 
calculations. As important as effectiveness, this study 
tested feasibility of the proposed oral hygiene regimen. 
Preoperative adherence to the oral hygiene regimen was 
high (87–100%). Postoperatively, 80% of patients opted to 
continue participation, with median adherence of 86% in 
this group. This revealed that patients were able to comply 
with the inexpensive oral hygiene regimen proposed. In 
summary, this study revealed that patients could adhere 
to a perioperative oral hygiene regimen that may hold 
promise for decreasing postoperative pneumonia rates. 
Small-scale studies like this are an affordable and realistic 
way of assessing feasibility of a new intervention while 
also gathering preliminary data before planning larger 
appropriately-powered studies to better test effectiveness. 
Prospective studies can also provide key insight into a 
particular disease process that is otherwise difficult to study 
through feasible means of subjective follow-up. An example 
of this is Giant Paraesophageal Hernias (GPEH) that are 
relatively rare and often misunderstood. Stringham et al. (6) 
studied 106 GPEH patients at a single institution and found 
that surgical repair is safe and carries a low postoperative 
complication rate. Additionally, the study compared a 
new, radiographic recurrence definition (any amount of 
stomach above the diaphragm on barium swallow) to the 
conventional recurrence definition most often used in 
GPEH literature (>2 cm or >10% of the stomach above 
the diaphragm) and found a 1-year radiographic recurrence 
rate of 32.7% compared to a conventional recurrence rate 
of 18.8%. Interestingly the patient satisfaction scores were 
similar between the smaller and larger GPEH recurrences 
(57.1% vs. 52.6%, respectively) but both were significantly 
higher than the overall preoperative satisfaction score 
average of 2.9%. Finally, this study used the validated 
quality of life metric (GERD-HRQL), where high scores 
suggest poor quality of life, to show that patients without 
recurrence had significantly improved scores from 22.5 to 
3.5 at 1 year from surgery, but that a recurrence of any kind 
was associated with an increase in score to 13.0. Prospective 
studies like this can help give thoracic surgeons a better 
understanding of a disease and specifically the subjective 
ramifications that it has on patient experience. This GPEH 
study was able to show convincingly the significant impact 
that a recurrence has on a patient postoperatively. It also 
revealed a potential new paradigm in the diagnosis of 
GPEH recurrence. This type of a prospective study was 
able to take advantage of a relatively small sample size, with 
a high follow-up rate (96.2% at 1 year) to gain outcome 
data about a surgical disease. With quality of life and other 
subjective indictors becoming more important in surgical 
patient care and potentially even in medical billing, small-
scale, feasible, prospective trials with high follow-up rates 
could provide thoracic surgeons much needed insight into 
the patient experience.
When a new treatment or intervention is introduced, 
multiple centers often discover similar shortcomings before 
independently adjusting and adapting. Small prospective 
studies on new practices can provide helpful insight into 
recognized trends, problems encountered, and knowledge 
gained that may be useful to many institutions. One example 
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is enhanced recovery after surgery (ERAS) pathways. There 
is a growing trend toward standardized ERAS protocols as 
data shows improved outcome measures with standardized 
and intentional postoperative care. These pathways can 
vary greatly between institutions. Martin et al. (7) at the 
University of Virginia introduced two thoracic ERAS 
protocols, one for VATS (n=81) and one for thoracotomy 
(n=58), and compared outcomes data to historic controls 
after 1 year. Both protocols showed significant decreases 
in postoperative opioids, total fluid balance, and hospital 
cost. ERAS after thoracotomy also showed a significant 
decrease in length of stay. While their preliminary data 
on the improvement of outcome measures is valuable, 
their detailed narrative of interventions made, problems 
encountered, and corresponding adjustments made to 
the pathway over the course of a year is widely useful to 
institutions developing similar protocols. By sharing this 
insight into the development of new interventions such as 
ERAS protocols, small prospective studies can encourage an 
efficient and collaborative approach across many institutions 
with the shared goal of improving patient experience. 
Stepwise improvements in patient care can result 
from studies like these. Appropriate design, analysis, 
and presentation of small-scale studies are critical for 
maximizing the impact of the findings, but the attributes 
highlighted here demonstrate the utility that a small or 
single-institution study can have within the field.
Con: these studies can have such significant 
limitations that they may have no meaningful 
impact
Small studies can be subject to inadequate statistical study 
design, methodological pitfalls, or other shortcomings that 
can severely limit their impact, or may preclude publication 
altogether. Potential limitations in study planning, conduct, 
analysis, and publication merit consideration.
One major risk with small or single-institution studies 
is that they may be underpowered and subject to type 
II error, meaning that even if there is a real effect of 
the intervention, the analysis may not show a statistical 
difference. One example of this is demonstrated by a small 
preliminary prospective randomized trial by Geddes et al. (8) 
that examined the effect of lung volume reduction surgery 
(LVRS) versus medical management for patients with 
severe emphysema. They randomized a total of 48 patients 
and found that, while there were statistically significant 
improvements in pulmonary function studies, walking 
distance, and quality of life, there was not an observed 
benefit in mortality with one strategy versus the other. In 
the subsequent National Emphysema Treatment Trial (9), 
which randomized a total of 1,218 patients to LVRS or 
medical treatment, there was sufficient statistical power 
to perform subgroup analyses based on the distribution of 
emphysema and baseline exercise capacity. This trial showed 
that for certain subgroups of patients with high baseline 
exercise capacity, there actually were significant differences 
in mortality: in predominantly upper-lobe disease, LVRS 
actually was associated with a lower risk of mortality, 
whereas for patients with non-upper lobe emphysema, 
LVRS carried a higher risk of mortality. These disparate 
findings are very important to patient selection, but were 
not apparent in smaller studies. The statistical power, or the 
ability to detect a difference in outcomes between groups if 
it exists, is predominantly dependent on sample size and the 
effect size of the intervention. Within a small-scale study, 
interventions that have a large effect may yield statistically 
significant results, while those that have a smaller, yet real, 
effect may not. While data on estimated effect size can 
be used to determine the necessary sample size to avoid 
a futile underpowered study, this is not always done for 
a variety of reasons, ranging from lack of availability of 
the necessary data in the context of preliminary studies to 
simply poor trial planning. Even if a goal sample size is 
estimated properly, it may not prove feasible to enroll the 
target number of patients in a single-institution study. It 
is therefore necessary to interpret negative results of small 
studies with trial design and statistical power in mind.
Another concern is the risk of false positive results, or a 
type I error. Rare events may have an unwarranted effect 
on a study’s conclusions if they occur in a small population, 
and this can pose a significant threat to the validity of a 
study. A notable example of such questionable findings is 
an analysis of stereotactic body radiation therapy (SBRT) 
versus lobectomy for stage I lung cancer (10), which pooled 
a total of 58 patients from two randomized trials (STARS 
and ROSEL) that were closed early due to poor enrollment. 
Of the 27 patients in the surgery group, 6 died, reflecting a 
much higher than expected mortality rate from lobectomy. 
Only one of the 31 patients receiving SBRT died, which 
resulted in their analysis showing a statistically significant 
difference in survival. A statistical study by Samson et al. (11) 
examined the stability of the survival estimates from 
small versus large cohorts of patients by performing a 
bootstrapping analysis of an institutional sample of stage 
I lung cancer patients who would have met criteria for 
S559Journal of Thoracic Disease, Vol 11, Suppl 4 March 2019
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inclusion in one of the randomized trials. They found that 
with a cohort of 27 patients (the actual number included in 
the pooled analysis), expected survival estimates at 3-year 
varied widely from 46–100%, whereas with a cohort of 515 
(the planned surgical enrollment of one of the randomized 
trials), the estimates ranged only from 70–85%. This is the 
reason that many clinical trials have planned preliminary 
analyses that take a very conservative early approach to 
avoid prematurely declaring superiority of a treatment 
based on chance events in a small sample size (12). Small 
studies that demonstrate much higher than expected event 
rates in one or both treatment arms should be interpreted 
with caution.
Additionally, confounding can be an issue in these 
studies. Randomization should theoretically distribute 
risk factors between intervention and control groups, but 
for practical reasons, many of these prospective studies 
are not randomized. As a result, an apparent effect of the 
intervention may in fact be due to one or more unequally 
distributed risk factors for the outcome of interest between 
the groups: confounding. A common approach to adjusting 
for potential confounding variables is performance of a 
multivariable analysis. A valid and reliable multivariable 
analysis including all relevant covariates may not be able 
to be performed with too few outcomes. A general rule is 
that ten outcomes are required for each variable included 
in the model (13), meaning that a small sample size in a 
study with few outcomes can preclude performance of 
a statistically sound multivariable analysis. Even when 
performed properly with sufficient outcomes, multivariable 
analysis only removes confounding from variables that were 
measured and included in the model, again emphasizing 
the importance of a properly designed study. Furthermore, 
some prospective studies are performed with a single 
interventional arm only, and initially encouraging results 
may not be confirmed when an intervention is tested in a 
trial, where additional important prognostic variables are 
taken into account. For example, Voynov et al. (14) reported 
outcomes from a series of 110 patients with stage I lung 
cancer who, because of poor lung function, underwent 
sublobar resection with placement of a brachytherapy mesh 
along the surgical margin and surrounding visceral pleura. 
They found an encouraging local control rate of 90% at 
5 years, prompting enthusiasm for use of brachytherapy. 
The subsequent ACOSOG Z4032 trial was performed (15) 
and 224 high-risk patients undergoing sublobar resection 
were randomized to receipt of brachytherapy versus surgery 
alone. This trial demonstrated that there was no difference 
in rates of local control (HR 1.01, P=0.98) or 3-year 
survival (71% for both groups, P=0.97). This demonstrates 
the importance of an appropriate comparison group and 
consideration of relevant covariates.
Another limitation is that results from small studies 
conducted in a single institution may not be reproducible 
or generalizable elsewhere. Idiosyncratic circumstances may 
exist at small centers that contribute to study outcomes. 
Additionally, if rigorous inclusion and exclusion criteria 
are implemented that significantly limit the population, a 
study may be assessing the efficacy of the intervention—
that is, how well it works in an ideal setting—rather than 
the effectiveness of the intervention—or how well it might 
be expected to work under more commonplace real-world 
circumstances (16). Often in studies, the patients most likely 
to benefit from an intervention are selected for participation 
through strict enrollment criteria. This frequently 
contributes to the ‘success’ of a study in demonstrating 
a statistically significant benefit of an intervention, but 
leaves providers questioning the expected benefit to their 
general patient population. The results may not be able 
to be extrapolated, or, while the intervention may still 
have an effect, it may be much smaller in magnitude than 
that demonstrated in the study. Attention to the patient 
population and study design can help a provider interpret 
how pragmatic the findings of a study are, and consideration 
of appropriate patient selection in trial planning can help 
maximize the applicability of the results. 
Finally, significant publication bias affects this type of 
study, even for properly executed trials: many of the studies 
that do not show a statistically significant difference may 
never be published. Many reasons for the lower rate of 
publication of negative studies are often cited, though the 
most common explanation is that they are never submitted 
for consideration. Often this is due to perceived lack of 
interest in the results, an assumption that a journal will not 
be willing to publish the study, or that there is no personal 
or patient benefit to publication of negative results (17). 
This bias in publication not only limits the available primary 
literature, but also can inappropriately impact the findings 
of systematic reviews and meta-analyses, leading essentially 
to inaccuracies in what is frequently considered the highest 
level of evidence (17).
Because of these potential shortcomings, small studies 
can sometimes be considered futile efforts. Alone, they may 
not provide sufficient credible evidence to modify practice 
within the field, or even for individual practitioners. The 
limitations reviewed here demonstrate why clinical practice 
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may not change in response to small or single-institution 
study findings.
Summary and recommendations
Consideration of certain elements can make for successful 
design and execution of small prospective studies. First, 
one should be mindful of several qualities in the conception 
and development of the project proposal. An appropriately 
focused clinical question must be selected. The effect of 
a single intervention should be investigated in a clearly 
defined patient population with specified inclusion and 
exclusion criteria. The trial itself needs to be properly 
designed, with an appropriate comparison or control group 
selected that is subject to the same predefined criteria. 
Randomization of patients to intervention or control groups 
is the gold-standard approach to minimize confounding, but 
time-matched, propensity-matched, or historical controls 
may be reasonable in certain circumstances. Thought 
should also be given to sample size. If preliminary data is 
available, power calculations should be performed to dictate 
target enrollment. For novel interventions, small pilot 
studies may be useful to assess feasibility of the intervention 
and to obtain a point estimate of effect size to perform power 
calculations for a planned larger trial. Furthermore, small-
scale studies are appropriate when testing an intervention that 
deviates from existing standard of care and may carry safety 
concerns. Interval analysis and monitoring should be planned. 
Careful design is critical to the success of a small trial. 
Second, adequate resources are needed to recruit and 
enroll patients. Cost-savings approaches to study design can 
help somewhat, but this is an especially relevant concern 
when significant costs may be associated with a single 
intervention or additional personnel are needed for detailed 
follow-up that is more in-depth than routine standard of 
care. Frequently, traditional sources of funding are granted 
on the basis of existing preliminary data. Sponsorship for 
the small trials that generate that initial data can be harder 
to come by. Industry, departmental, or societal support may 
be options in some cases. These avenues should be pursued, 
as having sufficient staff and support can be critical for 
meeting target enrollment and successfully conducting the 
intervention. Individual centers may be volunteering efforts 
to conduct these studies, which may not be sustainable or 
may substantially limit what can be done. There certainly 
is a need for more readily available funding to support 
promising efforts to conduct small-scale studies that may 
provide intriguing results or provide a basis for larger trials. 
Finally, it is essential to have an appropriate plan for 
analysis of the study data. Often, due to power and sample 
size concerns, there can be significant challenges getting 
these studies published. Clearly describing the purpose of 
the study and the design can be helpful when presenting 
pilot data. An analysis plan should be decided on a priori, 
and again it is critical to have a proper comparison group. 
Appropriate statistics should be used and the results should 
be reported with a discussion of the limitations. When 
conducted, analyzed, and presented appropriately, small 
studies can have an impact on the field.
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